announcement - lehman to present at biox , page-15

I guess it depend on your definition of "Corporate Update".

If it's simply a reprise of the changes in the management and board echelons of the company, I can't see that keeping a bunch of institutional investors in their seats at "beer o'clock".

My own interpretation of this is; it will be a summary of where the company has come from to date re Cvac trials, orphan drug status etc, what the near term holds for the ongoing trials and what the estimated size of the target market is.

This will likely be followed by a mad dash to the bar, where they can discuss the presentation over martini's. ;-)